Related Experiment Videos
Pharmacokinetics of intravenous omeprazole in children
E Jacqz-Aigrain1, M Bellaich, C Faure
1Department of Clinical Pharmacology, Hôpital Robert Debré, Paris, France.
Insights
This study defined the pharmacokinetics of omeprazole in children, finding highly variable parameters but overall similarity to adult profiles. Omeprazole was well tolerated across diverse pediatric patient groups.
Area of Science:
- Pharmacology
- Pediatric Medicine
- Drug Metabolism
Background:
- Omeprazole is a widely used proton pump inhibitor.
- Pediatric pharmacokinetic data for omeprazole is limited.
- Understanding drug behavior in children is crucial for safe and effective dosing.
Purpose of the Study:
- To characterize the pharmacokinetics of omeprazole in a heterogeneous pediatric population.
- To compare pediatric pharmacokinetic parameters with those reported in adults.
- To assess the tolerability of omeprazole in children.
Main Methods:
- A cohort of 13 pediatric patients (0.3-19 years) received varying doses of omeprazole.
- Pharmacokinetic parameters including systemic clearance, volume of distribution, and elimination half-life were analyzed.
- Patient age, disease state, and concomitant therapies were considered.
Main Results:
- Systemic clearance: 0.23 L/kg/h.
- Volume of distribution: 0.45 L/kg.
- Elimination half-life: 0.86 h.
- Significant inter-individual variability in pharmacokinetic parameters was observed.
- Pediatric parameters were comparable to adult values within the studied dose range.
- Omeprazole was well tolerated by all participants.
Conclusions:
- Omeprazole exhibits variable pharmacokinetics in children, influenced by factors like dosage and organ function.
- Despite variability, omeprazole's pharmacokinetic profile in children resembles that of adults.
- Omeprazole is a safe and well-tolerated medication for pediatric use.
Abstract:
This study was undertaken to define the pharmacokinetics of omeprazole in children and included 13 patients, heterogeneous in terms of age (0.3 to 19 years), underlying disease and biological constants, indication of omeprazole administration and associated therapy. The dose administered ranged from 36.9 to 139 mg.1.73 m-2. The pharmacokinetic parameters of omeprazole were: systemic clearance, 0.23 l.kg-1.h-1; volume of distribution, 0.45 l.kg-1; elimination half life 0.86 h; but were highly variable between individuals. Dosage, differences in hepatic and renal function and associated therapy may contribute to inter-individual variability. Within the range of doses administered, the pharmacokinetic parameters were similar to those reported in adults. The drug has been well tolerated in all children.